Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Bao‑Hui Han"'
Autor:
Wei Nie, Jun Lu, Jie Qian, Shu-Yuan Wang, Lei Cheng, Liang Zheng, Guang-Yu Tao, Xue-Yan Zhang, Tian-Qing Chu, Bao-Hui Han, Hua Zhong
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-17 (2024)
Abstract Background The association of body mass index (BMI) with survival outcomes in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line chemotherapy, immunotherapy, or chemoimmunotherapy is controversial. We aimed to
Externí odkaz:
https://doaj.org/article/a5cee6b3d13a4cd09b7e55edae57d2ec
Autor:
Ying Liu, Jia Fan, Jun Zhao, Tianshu Liu, Caicun Zhou, Shengxiang Ren, Ying Cheng, Caigang Liu, Xicheng Wang, Sheng Hu, Yufeng Cheng, Yueyin Pan, Shegan Gao, Yalun Li, Bao-Hui Han, Jifeng Feng, Shanyong Yi, Shanzhi Gu, Yongzhong Luo, Huijie Duan, Shuni Wang, Xinfeng Yang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 2 (2024)
Background The combination of immune-checkpoint inhibitors and antiangiogenic agents can synergistically modulate the tumor microenvironment and represents a promising treatment option. Here, we evaluated the efficacy and safety of camrelizumab plus
Externí odkaz:
https://doaj.org/article/e64460bcef6e43cab39d61f9e42164e6
Autor:
Wei Nie, Zhi-Jie Wang, Kai Zhang, Bing Li, Yi-Ran Cai, Feng-Cai Wen, Ding Zhang, Yue-Zong Bai, Xue-Yan Zhang, Shu-Yuan Wang, Lei Cheng, Hua Zhong, Li Liu, Jie Wang, Bao-Hui Han
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-12 (2022)
Abstract Background In non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (ICIs), higher blood tumor mutational burden (bTMB) was usually associated with better progression-free survival (PFS) and objective response ra
Externí odkaz:
https://doaj.org/article/7b068912172c438480424038ac194c0e
Publikováno v:
Chinese Medical Journal, Vol 133, Iss 20, Pp 2444-2455 (2020)
Abstract. In recent years, the research of immune checkpoint inhibitors has made a great breakthrough in lung cancer treatment. Currently, a variety of immune checkpoint inhibitors have been applied into clinical practice, including antibodies target
Externí odkaz:
https://doaj.org/article/e481f26c686640ab80870236412e066f
Autor:
Wei Nie, Lu Gan, Xin Wang, Kai Gu, Fang-Fei Qian, Min-Juan Hu, Ding Zhang, Shi-Qing Chen, Jun Lu, Shu-Hui Cao, Jing-Wen Li, Yue Wang, Bo Zhang, Shu-Yuan Wang, Chang-Hui Li, Ping Yang, Mi–Die Xu, Xue-Yan Zhang, Hua Zhong, Bao-Hui Han
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Somatic mutations of STK11 or KEAP1 are associated with poor clinical outcomes for advanced non-small-cell lung cancer (aNSCLC) patients receiving immune checkpoint inhibitors (ICIs), chemotherapy, or targeted therapy. Which treatment regimens work b
Externí odkaz:
https://doaj.org/article/43312b339c054c13bd77d56ebf24ec7f
Autor:
Wei Nie, Jie Qian, Mi-Die Xu, Kai Gu, Fang-Fei Qian, Min-Juan Hu, Jun Lu, Lu Gan, Xue-Yan Zhang, Shu-Hui Cao, Jing-Wen Li, Yue Wang, Bo Zhang, Shu-Yuan Wang, Fang Hu, Chang-Hui Li, Hua Zhong, Bao-Hui Han
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
A significant association between high blood-based tumor mutational burden (bTMB) and improved progression-free survival (PFS) was observed in advanced non-small cell lung cancer (NSCLC) receiving atezolizumab. However, this result was unrepeatable i
Externí odkaz:
https://doaj.org/article/9faefbc29ee74b6c80f8b06bacc4bfbf
Autor:
Qiang Lin, Qianqian Peng, Feng Yao, Xu-Feng Pan, Li-Wen Xiong, Yi Wang, Jun-Feng Geng, Jiu-Xian Feng, Bao-Hui Han, Guo-Liang Bao, Yu Yang, Xiaotian Wang, Li Jin, Wensheng Guo, Jiu-Cun Wang
Publikováno v:
PLoS ONE, Vol 7, Iss 3, p e34457 (2012)
Lung cancer is the leading cause of cancer death worldwide, but techniques for effective early diagnosis are still lacking. Proteomics technology has been applied extensively to the study of the proteins involved in carcinogenesis. In this paper, a c
Externí odkaz:
https://doaj.org/article/27a2b3cbcc2541bfa66eae12d418dcb3
Autor:
Ping Yang, Wei Nie, Jing Wen Li, Kai Gu, Lu Gan, Ding Zhang, Bao Hui Han, Fang Fei Qian, Xin Wang, Min Juan Hu, Shu Hui Cao, Midie Xu, Hua Zhong, Chang Hui Li, Bo Zhang, Shu Yuan Wang, Yue Wang, Jun Lu, Shi Qing Chen, Xue Yan Zhang
Publikováno v:
Oncoimmunology
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
article-version (VoR) Version of Record
OncoImmunology, Vol 10, Iss 1 (2021)
Somatic mutations of STK11 or KEAP1 are associated with poor clinical outcomes for advanced non-small-cell lung cancer (aNSCLC) patients receiving immune checkpoint inhibitors (ICIs), chemotherapy, or targeted therapy. Which treatment regimens work b
Autor:
Quanli C Zou, Zhijie Chang, Xiaoren Zhang, Dazhuan Eric Xin, Chao Huang, Jianmin Si, Bao-hui Han, Jinke Cheng, Rachel A. Altura, Li Ma, Li-shun Wang, Chuangui Wang, Ting C. Zhao, Y. J. Wang, Yongsheng Fan, Jing-Hua Yang, Xiong-Jun Wang, Min-dian Tan, Y. Eugene Chin, Yan S. Xu, Devasis Chatterjee, Ya-nan S. Zhang
Publikováno v:
Molecular Cell. 65:296-309
Summary In mammalian cells, histone deacetylase (HDAC) and Sirtuin (SIRT) are two families responsible for removing acetyl groups from acetylated proteins. Here, we describe protein deacetylation coupled with deacetylimination as a function of lysyl
Autor:
Ying Xiang, Shi Yue Li, Wei Jie Guan, Fa Guang Jin, Chang Gui Wu, Jie Wang, Cheng Ping Hu, Liang An Chen, He Ping Yang, Nanshan Zhong, Shou Zhi Liu, Qiang Li, Jian Ping Zhao, Guo Ming Wu, Jiang Huang, Bao Hui Han, Hui Ping Li, Guo Liang Xu, Xin Zhou
Publikováno v:
Lung Cancer. 98:43-50
Background Severe malignant airway obstruction (SMAO) is a life-threatening form of non-small cell lung carcinoma (NSCLC). Objectives To determine the efficacy and safety of para -toluenesulfonamide (PTS) intratumoral injection in NSCLC-SMAO. Methods